Earnings

Get news straight to your inbox by signing up for our free eNewsletters

Found 66,756 articles

  • On September 10, 2020, Luminex Corporation, announced that its board of directors declared a cash dividend for the third quarter of 2020 of $0.09 per share of common stock payable on October 15, 2020 to stockholders of record as of the close of business September 24, 2020.

  • Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported today its 2020 H1 financial results and provided a corporate update. " At Ryvu, we always excelled in moving forward at a rapid pace; however, the first half

  • Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the second quarter of fiscal 2021, the period ending July 31, 2020. All figures are reported in U.S. dollars.   Q2 ending July 31, 2020 Q2 ending July 31, 2019       Sales 1,377,747 1,243,883       Net Income 64,462 119,894       Income per common share   - basic 0.02 0.04                            

  • Strengthened financial position during H1 2020 with drawdown of IPF loan of EUR 10 million and a capital raise of EUR 17.7 million Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of type 2 diabetes in Q3 2020 and a target launch is expected in 2021 1 ; a milestone payment of EUR 4 million was received in Q3 2020 from Sumitomo Dainippon Pharma Initiated PXL065 Phase 2 trial in biopsy-proven NASH patients i

  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational progress for the half-year ended June 30, 2020. Highlights: Evenamide (Schizophrenia) All evenamide pre-clinical studies requested by the US Foo

  • BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020.

  • Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced it has filed its Quarterly Report on Form 10-Q for the quarter ended July 31, 2020.

  • Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2020.

  • Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, today announced its fiscal results for the quarter and year ended March 31, 2020 and provided an update on recent corporate developments.

  • PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M. David Seaburg, CEO, commented, “We continue to see strong execution and momentum in SkinTE sales. Further, we expect the expansion of our COVID-19 testing capabilities through a recently announced partnership to help drive continued revenue growth in our s

  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase

  • PPD, Inc., a leading global contract research organization, updated its financial guidance for the third quarter ending September 30, 2020.

  • The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.18 per share.

  • Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the third quarter ended July 31, 2020

  • The Bausch Foundation ("Foundation"), which oversees and directs the charitable giving efforts of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today released its Inaugural Activity Report , which highlights the

  • - Revenues for full year 2020 now expected to be $8.4-8.8 billion compared to the previous outlook of $8.0-8.6 billion - Reported diluted earnings per share (EPS) for full year 2020 now expected to be $7.42-$8.92 compared to the previous outlook of $5.66-$7.66 - Adjusted diluted EPS for full year 2020 now expected to be $7.50-$9.00 compared to the previous outlook of $6.60-$8.60 - Cash provided by operations for full year 2020 now expected to be at least $1.45 billi

  •  Selvita (WSE: SLV), one of the largest preclinical contract research organizations in Europe , reported today its H1 2020 financial results and provided a corporate update. For the H1 2020, Selvita reports consolidated revenues of EUR 15.2 million , up by 47% on a year-on-year basis. The EBITDA result reached EUR 3.6 mil

  • AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its financial results for the six months ended June 30, 2020. Financial Highlights for the First Six Months of 2020 Total revenues were RMB4.1 million (US$0.6 million) for the first six months of 2020, an increase of 3.4% from RMB3.9 million for the first six mo

  • Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces its unaudited interim results for the six months ended 30 June 2020.

  • MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2020.